Nutcracker Therapeutics Stock

Nutcracker Therapeutics raised $170 million in a Series C funding round to continue developing its RNA drug development platform. The company's preclinical lineup includes a multimodal RNA therapeutic for HPV-driven tumors, a patient-specific multimodal RNA therapeutic for T cell lymphoma, and a multimodal RNA therapeutic for genitourinary tumors. The company's in-house RNA production capability aids in eliminating common bottlenecks at the research and discovery stages, providing a cost-efficient platform for the screening of different protein constructs.

Nutcracker Therapeutics has appointed Cynthia Collins, a biopharma veteran and former CEO of Editas Medicine, to its board of directors. Collins brings over four decades of experience in the pharmaceutical and biotech industry and is currently the lead director at Panavance Therapeutics Inc. Her expertise in oncology, cell and gene therapies, and CRISPR will be crucial as Nutcracker Therapeutics prepares for its first clinical trial with lead candidate, NTX-250.